RT Conference Proceedings
T1 SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
A1 Ciruelos, E. M.
A1 Garcia, A. A.
A1 Cortes, J.
A1 Pernas Simon, S.
A1 Garate, E.
A1 Mele, M.
A1 Montano, A.
A1 Martinez-Janez, N.
A1 Oliveira, M.
A1 de la Haba-Rodriguez, J.
A1 Vega, E.
A1 Perello Martorell, A.
A1 Bermejo De Las Heras, B.
A1 Cantos Sanchez De Ibarguen, B.
A1 Martinez, E.
A1 Vila Navarro, E.
A1 Pascual, T.
A1 Gonzalez-Farre, X.
A1 Villagrasa, P.
A1 Prat, A.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-05-08
LK https://hdl.handle.net/10668/25898
UL https://hdl.handle.net/10668/25898
LA en
DS RISalud
RD Apr 11, 2025